There is no fulltext present in this item.

Find Full text  
Title: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Author(s): Biemans, V.B.C. ; Hoentjen, F. ; Pierik, M.J.
Publication year: 2020
Source: The New England Journal of Medicine, vol. 382, iss. 1, (2020), pp. 92
ISSN: 0028-4793
DOI: https://doi.org/10.1056/NEJMc1915739
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/220029   https://hdl.handle.net/2066/220029

Display more details
Subject: Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Gastroenterology
Journal title:
The New England Journal of Medicine
Volume: vol. 382
Issue: iss. 1
Page start: p. 92

This item appears in the following Collection(s)

Browse

Statistics